CT2 Program Lecture Series

All lectures are on Tuesdays from 12 to 1 p.m. in Comer Commons at Moores Cancer Center (directions and map). Lunch is available at 11:45 a.m. for those attending the lecture. 

Principles of Cancer Drug Therapeutics Development

This is a required series of 12 weekly lectures delivered by CT2 and UC San Diego faculty members during fall quarter. They focus on the necessary sequential steps in drug development.

Topics in Cancer Drug Development

This is a series of 10 monthly lectures by industry leaders in cancer drug development. The goal is to expose trainees to experts with a substantial track record in the “real life” challenges of cancer drug development. The lecturers are typically CEOs, directors of research, or medical directors from companies in the San Diego biomedical community, although experts from large pharmaceutical companies have also participated. The outside speakers are invited to discuss challenges of developing a given target or novel therapeutic and give fellows an opportunity to hear the story of the development of specific therapeutic agents.

Combined Schedule for 2012-13

Word Doc Printable version

Date Speaker Title
Sept. 18, 2012 Stephen Howell, MD
UCSD Hem/Onc
Introduction to Cancer Therapeutics Development
Sept. 25, 2012 Michael Jackson, PhD
Sanford Burnham
Discovery: high throughput screening for new drugs
Oct. 2, 2012 David Cheresh, PhD
UCSD
Targeting a non-canonical β3 integrin signaling axis reverses cancer stemness and resistance to EGFR inhibitors
Oct. 9, 2012 Hong Xin, PhD
Explora Biolabs
Cancer Drug Development and Pharmacokinetics
Oct. 16, 2012 Marque Todd, PhD
Pfizer

Principles of cancer drug toxicology

Oct. 23, 2012

Olivier Harismendy, PhD
UCSD

Translating genomic profiling into personalized cancer care

Oct. 30, 2012

Alice Yu, MD
UCSD/Optimer Biotechnology

Treatment of breast cancer by targeting globo H

Nov. 6, 2012

Erin Reid, MD
UCSD

The discovery and development of brentuximab vedotin

Nov. 13, 2012

Anjana Rao, PhD
La Jolla Institute for
Allergy and Immunology

TET proteins and 5-hydroxymethylcytosine in cancer

Nov. 20, 2012

Michael Bouvet, MD
UCSD

Fluorescence imaging in mouse models of cancer

Monday
Nov. 26, 2012

Thomas Kipps, MD
UCSD

The Mouse That ROR'ed

Dec. 4, 2012

Bill Fenical, PhD
UCSD

Marine Microbial Metabolites Provide Access to New Protein Targets for the Treatment of Cancer

Dec. 11, 2012 Scott Lippman, MD
UCSD
MCC Becoming Regional Academia-Industry Hub for Translating Discovery and Biomedical Invention to the Clinic
Dec. 18, 2012 William Rice, PhD
Cylene Pharmaceuticals
TBA
Jan. 8, 2013 Sandy Shattil, MD
UCSD
Integrin Signaling: Biomarkers and Therapeutic Targets in Neoplasia
Jan. 15, 2013 Fred De Sauvage
Genentech
Targeting the Hedgehog Pathway in Cancer: From Bench to Clinic
Jan. 22, 2013 Andrew McCammon
UCSD
Structure-based, Computer-aided Drug Discovery
Feb. 19, 2013 Geoff Wahl, PhD
Salk Institute
Investigating Breast Cancer from a Developmental Perspective
March 19, 2013 Patrick Vincent, PhD
Takeda
Opportunities, Risks, and Strategy of a Fast Follower Drug Discovery Program: Design and Development of MEK Inhibitors
April 16, 2013 Francis Burrows
Tragara
Who (And How) Do You Give the Drug With Everything? Developing a Multikinase Inhibitor for Cancer
May 21, 2013 Dietmar Berger
Genentech
TBA
June 11, 2013 Gregory Reyes
Celgene
TBA

Schedules for previous years